Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00759408 · ClinicalTrials.gov registry record · Phase 2
The Role of Endothelin in Pulmonary Hypertension
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT00759408 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 38 participants.
The verdict
NCT00759408, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of the study is is to determine the effect, on the lung circulation, of BQ-123, an investigational compound which is not approved by the FDA.
Interventions
- DRUG BQ-123
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 1999-02 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00759408
The ClinicalTrials.gov registry entry for NCT00759408 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BQ-123 is the first listed.
NCT00759408 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00759408 about?
NCT00759408 is a clinical study titled "The Role of Endothelin in Pulmonary Hypertension". The purpose of the study is is to determine the effect, on the lung circulation, of BQ-123, an investigational compound which is not approved by the FDA.
What is the current status of trial NCT00759408?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 1999-02. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00759408?
The interventions under investigation include: BQ-123 (DRUG).
Who is sponsoring clinical trial NCT00759408?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.